ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2018, Vol. 27 ›› Issue (1): 74-78.DOI: 10.3969/j.issn.1006-298X.2018.01.017

• 论文 • 上一篇    下一篇

内皮祖细胞和间充质干细胞治疗慢性肾脏病

  

  • 出版日期:2018-02-28 发布日期:2018-03-01

Progresses of endothelial progenitor cells and mesenchymal stem cells  therapy in patients with chronic kidney disease

  • Online:2018-02-28 Published:2018-03-01

摘要:

慢性肾脏病(CKD)的患病率呈逐年上升趋势,已成为全球重要的公共卫生问题,目前尚无有效的方法阻止其进展。以再生细胞为基础的治疗为CKD患者带来了新希望,内皮祖细胞(endothelial progenitor cells,EPCs)具有显著的促进血管再生的作用,而间充质干细胞(mesenchymal stem cells,MSCs)除了促进血管再生,还具有抗炎和抗纤维化作用,是干细胞治疗中最常用的两种细胞。本文对EPCs和MSCs的生物学特点和功能,及其在治疗CKD时面临的挑战和机遇作一综述。

关键词: 慢性肾脏病, 干细胞治疗, 内皮祖细胞, 间充质干细胞

Abstract:

Chronic kidney disease (CKD) has become the global health care burden with increasing growth rate every year, and now there is no effective treatment to impede the progress of CKD. Regenerative cell based therapies bring new hope for CKD. Endothelial progenitor cells (EPCs) contribute to neovasculogenesis, while mesenchymal stem cells (MSCs) also haave proangiogenic ability in addition to antiinflammatory and antifibrosis, both of them are commonly used for stem cell therapies. Recently, EPCs and MSCs make research boom in kidney disease. This review highlights current knowledge on EPCs and MSCs function and biology features, and reveals their opportunities and challenges in treatment of CKD.

Key words: chronic kidney disease, stem cell therapy, endothelial progenitor cell, mesenchymal stem cell